ArticleNeurology2024
Seizure Assessment and Forecasting With Efficient Rapid-EEG: A Retrospective Multicenter Comparative Effectiveness Study.
Erratum issuedAbstract readMulticenter StudyComparative Study
In one paragraph
Article in Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Continuous Versus Short EEG After Ischemic Stroke: What cEEG Adds for Detecting Abnormalities and Predicting Post-Stroke Epilepsy.Annals of neurology · 2026Article
- Point-of-Care EEG Artificial Intelligence Measure of Seizure Burden Associates With Clinical Outcome at Discharge.Critical care medicine · 2026Article
- Point-of-Care Electroencephalography in Acute Neurological Care: A Narrative Review.Neurology international · 2025Review
- Using artificial intelligence to optimize anti-seizure treatment and EEG-guided decisions in severe brain injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Correction to Author Disclosures.Neurology · 2024Article
- From prehospital care to the emergency department: current status and future directions of rapid EEG and artificial intelligence in the early recognition of status epilepticus.Frontiers in neurologyReview
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
19 authors.
Mariel Kalkach-AparicioFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.ORCID 0000-0002-3509-3548
Safoora FatimaFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Atakan SelteFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Irfan S SheikhFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.ORCID 0000-0002-0779-6297
Justine CormierFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Kaileigh GallagherFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Gayane AvagyanFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Jorge CespedesFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Parimala V KrishnamurthyFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Ahmed Abd ElazimFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Natasha KhanFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Omar M HusseinFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.ORCID 0000-0003-4853-0310
Rama MagantiFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Joshua LarocqueFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.ORCID 0000-0002-3697-9965
Smitha HollaFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Masoom DesaiFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.ORCID 0000-0002-6316-8404
Brandon WestoverFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Lawrence J HirschFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.ORCID 0000-0002-6333-832X
Aaron F StruckFrom the Department of Neurology (M.K.-A., R.M., A.F.S.), and Epilepsy Division of the Department of Neurology (S.F., A.S., G.A., P.V.K., J.L., S.H.), University of Wisconsin-Madison; Department of Neurology (S.F.), Southern Illinois University, Carbondale; Department of Neurology (A.S.), UCLA Harbor Medical Center, Torrance, CA; Epilepsy Division of Department of Neurology (I.S.S., K.G.), Massachusetts General Hospital, Boston; Comprehensive Epilepsy Center (J. Cormier, J. Cespedes, L.J.H.), Department of Neurology, Yale University, New Haven, CT; University of Connecticut School of Medicine (J. Cormier), Farmington; Epilepsy Division of Department of Neurology (K.G.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UHS Wilson Square Neurology (G.A.), Johnson City, NY; Universidad Autonoma de Centro America (UACA) School of Medicine (J. Cespedes), Granadilla, Cipreses, Costa Rica; Neurology Department (A.A.E., N.K., M.D.), University of New Mexico, Albuquerque; University of South Dakota (A.A.E.), Sanford School of Medicine, Vermillion; Comprehensive Epilepsy Team (O.M.H.), Neurology Department, University of New Mexico, Albuquerque; Center for Neuroengineering and Therapeutics (J.L.), University of Pennsylvania, Philadelphia; Department of Neurology (B.W.), Massachusetts General Hospital; and Beth Israel Deaconess Medical Center (B.W.), Boston, MA.
Funding
Prospective Validation of Neurophysiologic Outcome Prediction in Acute Brain InjuryR01NS126282 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Aaron F Struck, Michael Brandon Westover · 2023 to 2026
$2.9MNINDS NIH HHS R01 NS126282
Abstract
BACKGROUND AND
objectivesApproximately 30% of critically ill patients have seizures, and more than half of these seizures do not have an overt clinical correlate. EEG is needed to avoid missing seizures and prevent overtreatment with antiseizure medications. Conventional-EEG (cEEG) resources are logistically constrained and unable to meet their growing demand for seizure detection even in highly developed centers. Brief EEG screening with the validated 2HELPS2B algorithm was proposed as a method to triage cEEG resources, but it is hampered by cEEG requirements, primarily EEG technologists. Seizure risk-stratification using reduced time-to-application rapid response-EEG (rrEEG) systems (∼5 minutes) could be a solution. We assessed the noninferiority of the 2HELPS2B score on a 1-hour rrEEG compared to cEEG.
methodsA multicenter retrospective EEG diagnostic accuracy study was conducted from October 1, 2021, to July 31, 2022. Chart and EEG review performed with consecutive sampling at 4 tertiary care centers, included records of patients ≥18 years old, from January 1, 2018, to June 20, 2022. Monte Carlo simulation power analysis yielded n = 500 rrEEG; for secondary outcomes n = 500 cEEG and propensity-score covariate matching was planned. Primary outcome, noninferiority of rrEEG for seizure risk prediction, was assessed per area under the receiver operator characteristic curve (AUC). Noninferiority margin (0.05) was based on the 2HELPS2B validation study.
resultsA total of 240 rrEEG with follow-on cEEG were obtained. Median age was 64 (interquartile range 22); 42% were female. 2HELPS2B on a 1-hour rrEEG met noninferiority to cEEG (AUC 0.85, 95% CI 0.78-0.90, DISCUSSION: 2HELPS2B on 1-hour rrEEG is noninferior to cEEG for seizure prediction. Patients with low-risk (2HELPS2B = 0) may be able to forgo prolonged cEEG, allowing for increased monitoring of at-risk patients. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that rrEEG is noninferior to cEEG in calculating the 2HELPS2B score to predict seizure risk.
Indexed as
ElectroencephalographySeizuresAdultAgedComparative Effectiveness ResearchFemaleHumansMaleMiddle AgedRetrospective Studies
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.